Daniel O'Day, Gilead CEO (Photo by Paras Griffin/Getty Images for ESSENCE)
August 4, 2023 05:15 AM EDT
Pharma

Gilead touts speed­i­er-than-ex­pect­ed pipeline ad­vances amid sol­id Q2 drug sales, ex­cept Covid-19 treat­ment Vek­lury

Beth Snyder Bulik

Senior Editor

The key qual­i­fy­ing phrase to Gilead Sci­ences’ sol­id sec­ond quar­ter earn­ings was “ex­clud­ing Vek­lury.” That’s be­cause the Covid-19 treat­ment was the spoil­er dropoff in a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times